[{"orgOrder":0,"company":"Makana Therapeutics","sponsor":"Tonix Pharmaceuticals Holding Corp","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Collaboration","leadProduct":"TNX-1500","moa":"||CD154","graph1":"Nephrology","graph2":"Phase I","graph3":"Makana Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Makana Therapeutics \/ Makana Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Makana Therapeutics \/ Makana Therapeutics"}]

Find Clinical Drug Pipeline Developments & Deals by Makana Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Iran Expo
                          Not Confirmed
                          Iran Expo
                          Not Confirmed

                          Details : Tonix and Makana will study Tonix’s anti-CD40L monoclonal antibody candidate, TNX-1500, in combination with Makana’s human-compatible organs and cells for the treatment of organ failure.

                          Product Name : TNX-1500

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          April 09, 2025

                          Lead Product(s) : TNX-1500,Undisclosed

                          Therapeutic Area : Nephrology

                          Highest Development Status : Preclinical

                          Recipient : Tonix Pharmaceuticals Holding Corp

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank